The Company has now cash untill mid 2018 excluding Product Sales and new Partner Deals . A lot of big news are on the way which could push the stock much higher . Management and Institutions alone holding almost 70% of Company Shares . AQS is a must have at these ridiculous low price. This one has the potential to run like Biosyent (RX.V) which went from 0.10 to over $10 now at $7.50 .
Market-Cap: c$20.5 Million
Cash: c$5.1 Million << enough untill mid 2018
Price: $0.285
Must Watch
https://www.youtube.com/watch?v=jV00WmYBtv4
Presentation
https://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf
AQS1301 topline results in 1Q 2017
Operational profitability estimated in 2017
File for CDN approval of Topiramate XR in 1H 2017
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product Deals in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug commercialization in Canada
https://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada
James West: Sure. Have you built a pharmaceutical company before, Doug?
Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.
James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?
Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.
image: https://www.aequuspharma.ca/_images/Pipeline%202017%20EN.png?Action=thumbnail&algorithm=fill_proportional&width=750
